Our Pipeline
Our diverse pipeline is designed to meaningfully reduce the burden of vaccine-preventable diseases—and to make more diseases preventable.
Our diverse pipeline is designed to meaningfully reduce the burden of vaccine-preventable diseases—and to make more diseases preventable.
SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3) respiratory combination vaccine candidates are developed based on prefusion-stabilized F (PreF)-Trimer subunit vaccine antigens utilizing Clover's Trimer-Tag vaccine technology platform. In October 2025, Clover announced positive phase I clinical data for RSV+hMPV±PIV3 combination vaccine candidates in older adults. Results showed increases in neutralizing antibodies of approximately 6-8 fold for RSV, 6-9 fold for hMPV and 4 fold for PIV3 (≥10 fold increases in PIV3 PreF-specific antibodies), suggesting the potential for Clover’s RSV+hMPV±PIV3 combination vaccine candidates to both restore protection against RSV and broaden protection to hMPV±PIV3 in older adults (60-85 years).
SCB-1019 is a bivalent RSV-A/RSV-B vaccine candidate based on the prefusion-stabilized F (PreF) protein leveraging the validated Trimer-Tag platform and proprietary stabilizing PreF mutations.
In October 2024, Clover announced positive immunogenicity and safety data in older adult & elderly subjects from its Phase I trial evaluating SCB-1019 – the company's non-adjuvanted bivalent RSV prefusion-stabilized F (PreF)-Trimer subunit vaccine candidate, compared head-to-head with GSK’s AS01E-adjuvanted RSV vaccine (AREXVY). This made Clover become the first vaccine company announced clinical trial results globally evaluating Head-to-Head comparison with a licensed RSV vaccine (Market-Leading AS01E-adjuvanted AREXVY represents high bar).
In October 2025, Clover also announced positive phase I clinical data for RSV re-vaccination in older adults, and the interim analysis demonstrated ≥60% higher trend in RSV neutralizing antibodies for Clover’s RSV vaccine SCB-1019 compared head-to-head versus AREXVY (GSK) in older adults previously receiving an initial dose of AREXVY, indicating the potential ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore peak levels of RSV nAbs and protection.
Clover received Emergency Use Authorization (EUA) for SCB-2019 (CpG 1018/Alum) in China, and it was selected as the recommended vaccine in the “Implementation Plan for the Second Dose of Enhanced Immunization of COVID-19 Vaccine”.
SCB-219M is an innovative thrombopoietin receptor agonist (TPO-RA) mimetic bispecific Fc-fusion protein, for the treatment of cancer patients with chemotherapy-induced thrombocytopenia (CIT).
We have announced positive preliminary safety, efficacy and pharmacokinetics data in a Phase I clinical trial in the end of 2023.
